, and Deputy CEO Franz-Werner Haas was put in control of the company.
On March 12, the day after news was released of the CEO switch, Hoerr spoke with Business Insider about CureVac's research and the recent change in leadership. The conversation took place before press reports about a reported offer from US officials for its vaccine work. "I think every phase has a CEO fitting for the company," Hoerr said. "[Menichella] had a good fit the last two years, and now I might have a good fit now to get these things done and get to the market."
He also stressed that CureVac has the ability to mass produce a vaccine if needed in a time of emergency. He outlined how an early safety study, called a Phase 1 trial, could expand to a large population in the case of an emergency:
DecriminaliseAllDrugUseNow CORONAVIRUSUPDATE
I want to know about the other ~25companies they were talking to.
ประเทศไทย ข่าวล่าสุด, ประเทศไทย หัวข้อข่าว
Similar News:คุณยังสามารถอ่านข่าวที่คล้ายกันนี้ซึ่งเรารวบรวมจากแหล่งข่าวอื่น ๆ ได้
แหล่ง: BusinessInsider - 🏆 729. / 51 อ่านเพิ่มเติม »
แหล่ง: BusinessInsider - 🏆 729. / 51 อ่านเพิ่มเติม »
แหล่ง: Forbes - 🏆 394. / 53 อ่านเพิ่มเติม »